Amneal Pharmaceuticals(US:AMRX)2025-05-02 10:32Financial Performance & Growth - Q1 2025 revenue reached $695 million, a 5% increase year-over-year[10] - Adjusted EBITDA for Q1 2025 was $170 million, up 12% compared to Q1 2024[10] - Adjusted EPS for Q1 2025 increased by 50% to $0.21[10] - The company affirms its full-year 2025 revenue guidance of $3.0 - $3.1 billion, representing a 7% to 11% growth[59] - Adjusted EBITDA for 2025 is projected to be $650 - $675 million, a 4% to 8% increase[59] Business Segment Performance - Affordable Medicines segment revenue grew by 6% to $415 million in Q1 2025[58] - Specialty segment revenue increased by 3% to $108 million in Q1 2025[58] - AvKARE segment revenue also grew by 6% to $172 million in Q1 2025[58] Key Products & Pipeline - CREXONT® is experiencing strong script growth and expanding coverage, reaching approximately 60%[10] - Eight new products have been launched in 2025, including BORUZUTM, a 505(b)(2) injectable[10] - Two denosumab biosimilar Biologics License Applications (BLAs) have been filed[10] Debt & Leverage - Net leverage stands at 3.9x as of March 31, 2025[17]